Trial · NCT06545500
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Average Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) | Baseline (pre-dose for each treatment period) and Day 7 | |
| Secondary | Change From Average Baseline FEV1 to Average Peak FEV1 Measured Over 4 Hours | Baseline (pre-dose for each treatment period) and Day 7 | |
| Secondary | Change From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 4 Hours (AUC0-4h) | Baseline (pre-dose for each treatment period) and Day 7 | The endpoint is measured as AUC/4 hour time interval resulting in an average volume measure in liters. |
| Secondary | Change From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 12 Hours (AUC0-12h) | Baseline (pre-dose for each treatment period) and Day 7 | The endpoint is measured as AUC/12 hour time interval resulting in an average volume measure in liters. |
| Secondary | Change From Average Baseline FEV1 to Evening Trough FEV1 | Baseline (pre-dose for each treatment period) and Day 7 | |
| Secondary | Change From Average Baseline FEV1 to Peak FEV1 Measured Over 4 Hours After First Dose | Baseline (pre-dose) and Day 1 | |
| Secondary | Change From Average Baseline FEV1 to Average FEV1 AUC0-4h Measured After First Dose | Baseline (pre-dose) and Day 1 | The endpoint is measured as AUC/4 hour time interval resulting in an average volume measure in liters. |
| Secondary | Number of Treatment Emergent Adverse Events (TEAEs) | From first dose through the follow-up contact (approximately 8 weeks per participant). Overall safety data was collected for 5 months total. | |
| Secondary | Glycopyrronium Free Base AUC0-12h | After morning dose Day 7 | |
| Secondary | Glycopyrronium Free Base Maximum Plasma Drug Concentration (Cmax) | After morning dose Day 7 | |
| Secondary | Glycopyrronium Free Base Time to Maximum Plasma Drug Concentration (Tmax) | After morning dose Day 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06545500/registered